UPDATE : 2021.2.25 13:53

South Korean drug delivery company Lemonex wins Trade, Industry and Energy Minister's prize at the Innovation Winner 2020 for innovative DegradaBALL drug delivery technology

l2021.01.19

ũ

۰

μ

Ű

   
Lemonex / CEO Cheolhee Won, CTO Dal-Hee Min

Lemonex is a South Korean biotherapeutics and biotechnology company boasting next-generation innovative drug delivery and biosensor technologies. Based on these innovative technologies, CEO Cheolhee Won, CTO Dalhee Min and the excellent research team focus on the development and commercialization of cancer immunotherapeutics, antibody therapeutics and gene therapeutics.

DegradaBALL®, the original technology of Lemonex, enables the effective delivery of various drug candidates into the cultured cells or lesions by loading the drugs inside. It is a next-generation drug delivery technology optimized especially for the development of gene therapy, cancer immunotherapy, antibody therapy, and synthetic drugs. 

Pre-existing drug delivery vectors such as liposomes, micelles, and exosomes are inappropriate in maintaining the size of the particles, the certain level of the concentration of the drug loaded, and the stability of drug delivery system at room temperature. 

Lemonex's innovative DegradaBALL®, on the other hand, enables the control over the size, the concentration, and the stability with convenient procedure. Also Lemonex' innovative PANGO® technology, is the next-generation drug screening technology that allows the rapid screening of antiviral drugs from drug candidate library and it is optimized for the development of therapeutic agents against novel viruses.

The Nobel Prize winning siRNA once attracted a great attention in the industry but turned out to have a short half-life, delivery inefficiency, side effect and thus lost commercial feasibility so as the ongoing development pipeline in early 2010. The Alnylam Pharmaceuticals' patisiran and givosiran also once pushed the company surpassing 10 billion USD market capitalization but turned out to have certain limitations. 

Good news, however, is that siRNA medicine passed the FDA approval and global pharmaceuticals are beckoning siRNA enterprises. Eli Lilly, for example, invested 100 million USD in a venture siRNA developer Dicerna in 2018, J&J signed a contract with Arrowhaed for siRNA medicine for hepatitis B, and Alnylam with Regeneron for 1 billion USD worth joint research.

Lemonex's innovative DegradaBALL® focuses on RNA medicine usually categorized in siRNA medicine and mRNA medicine. The latter is attracting attention in relation with COVID-19 vaccine. The core of both medicines lies at delivering the therapeutic substances into the targeted cells and maintains its effectiveness. 

Lemonex's innovative DegradaBALL® has been proved to hold the therapeutic substances and its effectiveness longer inside and can be used to make medicines or vaccines to treat and prevent various diseases. LEM-S401 (DegradaBALL®-grafted siRNA medicine) has passed NHP (Nonhuman Primate) preclinical trials with excellent marks and the phase 1 clinical trials have been scheduled to be carried out in early 2021. 

CEO Cheolhee Won also has built cooperation platform with Prof. Brian Berman and Prof. Alexander Meves, global authorities of skin plastic surgery and dermatology, to continue global level clinical developments. 

On the closing month of the year 2020 in which most of people on earth were still struggling to fight against the pandemic, Lemonex received the Trade, Industry and Energy Minister's prize at the Innovation Winner 2020 in the technology innovation category. PowerKorea → powering Korean companies to the world!

ުܻԸ药ڪ传递术掀风
韩国坚业创奖获产业资ݻݻ长奖
亿ڸ业独兽业进发

随ήϹ们来关医学术药风险资过条研发η线研发种药备们关Lemonexɣ执ί术ί闵达药ڪ传递载体DegradaBALL®术启动剂RNA疗剂两条研发η线疗过飬ܻ剂极ԸģLemonex研发种٣为BALLkine-2ݻ给药剂从ܻ对检查剂体药ڪ应㣬减ġή让mRNA疗剂备瞩ͣmRNA疗剂RNA疗剂á举韩国坚业创奖飬Lemonex获奖项——产业资ݻݻ长奖笔将Lemonex选为热闻业进访

研发ުܻԸ药ڪ传递术——DegradaBALL®
与Ϲ药协种联研ϼ研发

Lemonexʫ开发药ڪ传递载体DegradaBALL®术剂RNA疗剂ɡLemonex为ʫϹڪ疗ɣ研发ުܻԸ药ڪ传递术DegradaBALL®
DegradaBALL®弥补产裬让RNA药达ܣ时还将药给体带来˽Lemonex仅够过构GMP设实现产还拥产术进军Ϲ临开发Ϲ场评Lemonexʦ说变剂RNA疗剂领戏规则ɣLemonex与Ϲ药协种联研ϼ研发
2006Ҵ诺贝尔医学奖siRNA疗剂获Ϲ药广关񼡣ӣsiRNA体内Ѣ过ӭ电负很难过传递细内质体质纳ڷأ载体传递ӣ传递浓siRNA仅经济药难发挥还红衢过应ģ续研发难进21纪10ҴϹ药ݻ关研发η线断drop򭣨stop

获2020届韩国坚业创奖
亿ڸ业独兽业进发

Lemonex过DegradaBALL®术RNA疗剂研ϼRNA疗剂ʦ为两种种ܻ关达siRNA疗剂另种ή备关mRNA疗剂
两种疗剂Դ将RNA疗ڪ质传递细内并续发挥药质载体Lipid Nanoparticle; LNP很ã顢传递Ѣӭ药难长时间续죡药ڪݻ传递ܣ难研发ܻ疗剂߲-70°C环׵ס
Lemonex研发DegradaBALL®够载߾RNA疗ڪ质并够体内长时间续发挥药ʦDegradaBALL®研发肿׻肤ѿ个组织ί疗剂ࡣ
Lemonex经研发够к߾RNA疗剂DegradaBALL®术并构产体ͧ与DegradaBALL®术结siRNA疗剂LEM-S401猴(NHP)临实验并优异绩计划2021Ҵ߾Ҵ进ϹѢ临实验Lemonex还޽请肤Ρ学肤肿׻学领权专ʫڸ国肤协会会长ڸ国药监Խη审议专ʫ组员赖·尔غ教⣣Brian Bermanڸ国奥医学亚历ߣ·维教(Alexander Meves)组Ρ学询员会SAB, Scientific Advisory Board进军Ϲ临开发ڸ国场ഡ
过Lemonex断ҽ2020Ҵ1217릡韩国驱报驱经济报办韩国Power Korea办2020届韩国坚业创奖获“术创类产业资ݻݻ长奖”
2020Ҵ7Lemonex亚设ءLemonex Pty LtdLemonex为进军Ϲ场跃为亿ڸ业独兽业断ҽѢLemonex够凭术实Ϲ场掀场创风

独ު뫹ɫëǫЫー発

国̱Ϋー۪˪ߧݻ総۪
˫ー˪ʪ몿Ϋーȫ髤ء

ʫ뫹国内拡ުƪ顢医学々関ުêƪ롣ȡ薬会٫ーǪϣĪΫѫ׫髤ĪĪ医薬発롣対()ͫë・CEO߫・CTOϫɫëǫЫー׫ëȫիーǪDegradaBALLĪ몳Ȫǡ剤RNA伝薬ȪĪΫѫ׫髤ªͪ鱪Ӫƪ롣Φ˪ơ経験剤ԸĪпʾު()ͫë湫ëݫ薬体医薬対応ԪᡢĪ몿п与Ϊ剤Ǫ롸BALLkine−発ƪ롣ުRNA伝薬˪ʫ뫹Ϋ﫯Ȫݩ߾ƪRNA剤ߪުƪ몿ᡢު˪ʪêƪ Ϊ誦ت顢檷国̱ΫΫー۪˪۪Ǫߧݻ総۪۪()ͫë2021Ҵ巻Ū˪ーުȪ߾몳Ȫ˪

独ު뫹ɫëǫЫーDegradaBALL
ーЫ薬会ܪ研ϼӫӫͫ発Ϊ渉
()ͫëϡɫëǫЫー׫ëȫիーǪDegradaBALLĪ剤RNA伝薬発ƪ専ڦǪ롣剤RNA伝薬発뫰ーЫ・Ыーԫーƫ専ڦǪꡢ独ު뫹ɫëǫЫーDegradaBALL発
DegradaBALLϡ従来ΫɫëǫЫーȪܬתRNA医薬効ĪǪʪĪ몳ȪǪ롣独GMP内ݻߧʦʪǪʪߧĪーЫ発ӫーЫު󪹪몿ЪȪ価ƪ롣()ͫëϡ剤RNA伝薬Ϋー󫸫ーȪƫーЫ薬会ܪ研ϼӫӫͫ発몿渉ƪ롣
siRNA剤2006Ҵー٫学医学۪۪来ーЫ薬会ުͪƪsiRNA体ǪѢпӭ䫤Īᡢ内Ԫʫ᫫˫ȪƫǫЫー몳Ȫ񪷪liposomelipidnanoparticleǫЫーڪȪĪΪΡsiRNA薬ʪЪʪʪᡢǪʪ体内˪薬効ƪΪ単ʪȪǪϪʪêˡƫޫーǫʫի髭ー応ʪɪĪުǪêᡢʥܪ発実ު񪷪断쪿̿2010Ҵ۪ᡢーЫ薬会ϡ発ƪѫ׫髤drop몤stop

2020歔・国̱ΫΫーۡ
˫ー˪ʪ몿Ϋーȫ髤ء()ͫëDegradaBALLĪ몿ˡڪǪΪRNA剤寪Ǫ롣RNA剤ϡܪ関֧伝発ުǪsiRNA剤CoVID-19Ϋ﫯Ȫݩ߾ƪmRNA剤ª몳ȪǪ롣
両۰ȪRNAڪ内届薬効続몳ȪーȪʪ롣従来ΫɫëǫЫー体ǪʫLipid NanoparticleLNPϡǫЫー効㪬߾Ѣӭᡢ薬効続몳Ȫ񪷪体内与Ϫ۪Ȫɪ臓˫ǫЫー졢臓剤発Ϊ乱Ǫ롣ު޼°Cη・׵תʪЪʪʪʪ数ӭᶪ롣
()ͫë発DegradaBALLϡΪ誦RNAڪ内ݻ몳ȪǪ몿ᡢ体与薬効続몳ȪǪ臓ˡݱ뿪ʪ様Ī臓Ū剤・﫯発ʦȪʪ롣
()ͫëLemonex Inc߾RNA剤ͣкת몿DegradaBALL発ߧƫϰ骷DegradaBALLĪsiRNA剤LEM-S401ުҫ霊׾NHP験⳪ƪꡢ2021Ҵ߾Ѣ˫ーЫɣɪͪ画Ǫ롣ުΡ学ꬣSAB,Scinetific Advisory BoardȪơݱΡ学ݱ学寪ΫȫëתǪ֫髤・ーޫ教⣣ꫫݱ会ꫫFDA専ڦʫѫͫ룩ȫ쫯ー・֫教⣣ꫫMayo Clinic٤ーЫ発ӫꫫު󪹪몿ЪĪ
Ϊ誦挙̿()ͫëҴ1217ث経済ꫢثɪʪʫѫーꫢη2020歔国̱ΫΫーۡ˪ơߧݻ総ۡΫーݻڦ۪
()ͫëҴ7šーȫꫢ会ΡLemonex Pty LtdءȪ﷪ˡϫーЫުت󪪪ӫ˫ー˪ʪ몿実ƪ롣()ͫëԪ駆ŪーЫު檷ΫーêᴪǪĪ۾몳Ȫѷ롣


  powerkorea_j@naver.com
<۱ © Ŀڸ, >

ٸ
ŹҰŰ޹ħûҳ⺸ȣå̸Ϲܼź
ظŰ Ŀڸ ǥ   |   Ư ߰ 162-3 2  |  ǥȭ : 02-466-5085  |  ѽ : 02-444-0454
ǥ/ޱ : bridgekorea@naver.com  |  å : (bridgekorea@naver.com)  |  ڵϹȣ : 212-23-25879
ûҳ⺸ȣå :
Copyright © 2008 - 2021 Ŀڸ. All rights reserved.